Literature DB >> 12704577

Trends in the epidemiology of focal segmental glomerulosclerosis.

Chagriya Kitiyakara1, Jeffrey B Kopp, Paul Eggers.   

Abstract

There is marked variation in the frequency of focal segmental glomerulosclerosis (FSGS) around the world. Recent studies of renal biopsy specimen archives from several institutions in the United States suggest that the incidence of FSGS has increased over the past 20 years. Indeed, FSGS has become the leading cause of idiopathic nephrotic syndrome in adults and has become increasingly common in children as well. Further, the data indicate that black individuals are at increased risk for developing idiopathic FSGS as well as FSGS in the setting of human immunodeficiency virus (HIV)-1 infection. Data from around the world suggest great variability in the proportion of glomerular disease that is attributed to FSGS, with recent increases seen in some countries and not in others. Epidemiologic data from the United States Renal Data Systems (USRDS) show that the incidence of end-stage renal disease (ESRD) owing to idiopathic FSGS has increased considerably, both as absolute numbers and as a fraction of the total ESRD incident population, with FSGS now accounting for 3.3% of incident ESRD cases. In the United States, the annual rate of incident FSGS ESRD cases is 7 per million for the general population, 20 per million for black individuals, and 5 per million for white individuals. The numbers of acquired immune deficiency syndrome (AIDS) nephropathy incident ESRD cases increased rapidly until reaching a plateau after 1995. The reasons for the recent increase in idiopathic FSGS and FSGS incident ESRD cases are complex, but these trends are likely caused, at least in part, by a real increase in the incidence of FSGS over the past 10 to 20 years. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2003        PMID: 12704577     DOI: 10.1053/snep.2003.50025

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  72 in total

1.  Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin.

Authors:  Tobias B Huber; Christopher Kwoh; Hui Wu; Katsuhiko Asanuma; Markus Gödel; Björn Hartleben; Ken J Blumer; Jeffrey H Miner; Peter Mundel; Andrey S Shaw
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

2.  A new locus for familial FSGS on chromosome 2p.

Authors:  Rasheed Gbadegesin; Peter Lavin; Louis Janssens; Bartlomiej Bartkowiak; Alison Homstad; Guanghong Wu; Brandy Bowling; Jason Eckel; Chris Potocky; Diana Abbott; Peter Conlon; William K Scott; David Howell; Elizabeth Hauser; Michelle P Winn
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

3.  An explorative analysis of secretory receptor for advanced glycation endproducts in primary focal segmental glomerulosclerosis.

Authors:  Harin Rhee; Sang Heon Song; Ihm Soo Kwak; Il Young Kim; Eun Young Seong; Dong Won Lee; Soo Bong Lee
Journal:  Clin Exp Nephrol       Date:  2012-08       Impact factor: 2.801

Review 4.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

5.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Authors:  Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

Review 6.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

7.  Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS.

Authors:  Limin Li; Tao Zhang; Wenli Diao; Fangfang Jin; Lei Shi; Jiao Meng; Huan Liu; Jing Zhang; Cai-Hong Zeng; Ming-Chao Zhang; Shaoshan Liang; Yuan Liu; Chen-Yu Zhang; Zhihong Liu; Ke Zen
Journal:  J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 10.121

8.  Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients.

Authors:  Pankaj Srivastava; Ashish K Solanki; Ehtesham Arif; Bethany J Wolf; Michael G Janech; Milos N Budisavljevic; Sang-Ho Kwon; Deepak Nihalani
Journal:  Kidney Int       Date:  2019-01-29       Impact factor: 10.612

Review 9.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

10.  African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans.

Authors:  Doron M Behar; Saharon Rosset; Shay Tzur; Sara Selig; Guennady Yudkovsky; Sivan Bercovici; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Walter G Wasser; Karl Skorecki
Journal:  Hum Mol Genet       Date:  2010-02-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.